keyword
MENU ▼
Read by QxMD icon Read
search

Ild

keyword
https://www.readbyqxmd.com/read/29785507/assessing-mortality-models-in-systemic-sclerosis-related-interstitial-lung-disease
#1
Robert L Mango, Eric L Matteson, Cynthia S Crowson, Jay H Ryu, Ashima Makol
PURPOSE: The gender, age, and lung physiology (GAP) model, interstitial lung diseases-GAP (ILD-GAP) model, and the smoking history, age, and diffusion capacity of the lung (SADL) model were compared using a systemic sclerosis-ILD (SSc-ILD) cohort to evaluate which best determined prognosis. METHODS: The models were applied to a cohort of 179 patients with SSc seen at a tertiary care center within 1 year of ILD diagnosis. Demographics, clinical characteristics, and mortality were recorded...
May 21, 2018: Lung
https://www.readbyqxmd.com/read/29782426/nailfold-videocapillaroscopy-changes-are-associated-with-the-presence-and-severity-of-systemic-sclerosis-related-interstitial-lung-disease
#2
Joana Caetano, Filipe S Paula, Marta Amaral, Susana Oliveira, José D Alves
OBJECTIVE: The aim of this study was to evaluate the association of nailfold videocapillaroscopy (NVC) changes with the presence and severity of interstitial lung disease (ILD) in systemic sclerosis. METHODS: This was a cross-sectional analysis of 48 systemic sclerosis patients (21 patients with ILD). The NVC characteristics considered were capillary organization, capillary loss (CL), avascular areas, enlarged and giant capillaries, hemorrhages, abnormally shaped capillaries, edema, and intermittent flux...
May 19, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29782069/efficacy-and-safety-of-nivolumab-in-non-small-cell-lung-cancer-with-preexisting-interstitial-lung-disease
#3
Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai
BACKGROUND: The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the treatment of non-small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexisting ILD, the risk of ICI-related pneumonitis is unknown. We evaluated the efficacy and lung toxicity of nivolumab in patients with NSCLC and ILD. METHODS: We retrospectively reviewed the medical records of 216 NSCLC patients who had received nivolumab therapy...
May 21, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29781586/treatment-algorithms-for-systemic-sclerosis-according-to-experts
#4
Andreu Fernández-Codina, Kyle M Walker, Janet E Pope
INTRODUCTION: Treatment for many aspects of systemic sclerosis (SSc) lacks agreement. OBJECTIVES: To generate SSc treatment algorithms endorsed by high percentage of SSc experts. METHODS: Experts from the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research group (N=170) were asked whether they agreed with SSc algorithms (from 2012). Two consensus rounds refined agreement; 62 (36%), 54 (32%) and 48 (28%) experts completed surveys...
May 21, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29779392/heterogeneity-in-unclassifiable-interstitial-lung-disease-a-systematic-review-and-meta-analysis
#5
Sabina A Guler, Kina Ellison, Mohmmed Algamdi, Harold R Collard, Christopher J Ryerson
BACKGROUND: Accurate diagnosis of interstitial lung disease (ILD) is necessary to identify the most appropriate management strategy and to inform prognosis. Many patients cannot be provided a confident diagnosis despite an exhaustive search for potential etiologies and review in a multidisciplinary conference; and are consequently labelled with unclassifiable ILD. OBJECTIVE: to systematically review and meta-analyse previous studies reporting on the diagnostic criteria, prevalence, clinical features, and outcome of unclassifiable ILD...
May 20, 2018: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/29777409/hemodynamic-heterogeneity-of-connective-tissue-disease-patients-with-borderline-mean-pulmonary-artery-pressure-and-its-distinctive-characters-from-those-with-normal-pulmonary-artery-pressure-a-retrospective-study
#6
Yusa Asari, Yoshioki Yamasaki, Kosei Tsuchida, Kengo Suzuki, Yoshihiro J Akashi, Takahiro Okazaki, Shoichi Ozaki, Hidehiro Yamada, Kimito Kawahata
To clarify whether patients with connective tissue disease (CTD)-associated borderline mean pulmonary artery pressure (mPAP) have distinctive hemodynamic characteristics from those with normal mPAP and whether pathogenesis is as heterogeneous as manifest pulmonary hypertension (PH). Seventy-five CTD patients who underwent right heart catheterization (RHC) from 2008 through 2016 were retrospectively analyzed. We compared between-group differences in clinical and hemodynamic findings: normal mPAP (n = 35), borderline mPAP (n = 15), and PH (n = 25)...
May 18, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29776943/mycophenolate-mofetil-induced-colitis-in-a-patient-with-systemic-sclerosis
#7
Gianluca Moroncini, Devis Benfaremo, Alessandra Mandolesi, Armando Gabrielli
We present the case of a 44-year-old woman affected by systemic sclerosis (SSc) who was admitted to our department for abdominal pain, nausea, vomiting and fever. Imaging studies showed the presence of a thickened colon wall involving the descending colon and the sigma, while a subsequent endoscopy revealed multiple serpiginous ulcers covered with fibrin and exudates. Under the hypothesis of drug-induced colitis, mycophenolate mofetil (MMF), which she was taking for SSc-related interstitial lung disease (ILD), was readily suspended, with a rapid recovery without further treatment...
May 18, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29776440/radiological-pleuroparenchymal-fibroelastosis-associated-to-limited-cutaneous-systemic-sclerosis-a-case-report
#8
D Hassoun, S Dirou, P P Arrigoni, C Durant, M Hamidou, A Néel, C Agard
BACKGROUND: Pleuroparenchymal fibroelastosis (PPFE) is a very rare interstitial lung disease (ILD) characterized by progressive fibrotic lesions of the visceral pleura and the sub-pleural parenchyma, affecting predominantly the upper lobes. PPFE may occur in different contextes like bone marrow or lung transplantations, but also in the context of telomeropathy with mutations of telomerase reverse transcriptase (TERT), telomerase RNA component (TERC) or regulator of telomere elongation helicase 1 (RTEL1) genes...
May 18, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29775809/transient-asymptomatic-pulmonary-opacities-during-osimertinib-treatment-and-its-clinical-implication
#9
Hansang Lee, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Youjin Kim, Song Ee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
INTRODUCTION: Osimertinib is an oral, potent, irreversible 3rd generation EGFR tyrosine kinase inhibitor (TKI) approved for the treatment of T790M positive non-small cell lung cancer (NSCLC) patients who failed 1st or 2nd generation EGFR TKIs. Interstitial lung disease (ILD) is a rare complication with osimertinib, occurring in 1-3%. Recently, relatively high incidence of transient asymptomatic pulmonary opacities (TAPOs) which are different from ILD has been described. However, its clinical implication has not been fully determined yet...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29770107/murburn-concept-a-molecular-explanation-for-hormetic-and-idiosyncratic-dose-responses
#10
Abhinav Parashar, Daniel Andrew Gideon, Kelath Murali Manoj
Recently, electron transfers and catalyses in a bevy of redox reactions mediated by hemeproteins were explained by murburn concept. The term "murburn" is abstracted from " mur ed burn ing " or " m ild u n r estricted burn ing " and connotes a novel " m olecule- u nbound ion- r adical " interaction paradigm. Quite unlike the genetic regulations and protein-level affinity-based controls that govern order and specificity/selectivity in conventional treatments, murburn concept is based on stochastic/thermodynamic regulatory principles...
April 2018: Dose-response: a Publication of International Hormesis Society
https://www.readbyqxmd.com/read/29769294/pulmonary-function-tests-as-outcomes-for-systemic-sclerosis-interstitial-lung-disease
#11
REVIEW
Melissa Caron, Sabrina Hoa, Marie Hudson, Kevin Schwartzman, Russell Steele
Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). We performed a systematic review to characterise the use and validation of pulmonary function tests (PFTs) as surrogate markers for systemic sclerosis-associated interstitial lung disease (SSc-ILD) progression.Five electronic databases were searched to identify all relevant studies. Included studies either used at least one PFT measure as a longitudinal outcome for SSc-ILD progression ( i.e. outcome studies) and/or reported at least one classical measure of validity for the PFTs in SSc-ILD ( i...
June 30, 2018: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29768275/predictive-factors-for-the-long-term-deterioration-of-pulmonary-function-in-interstitial-lung-disease-associated-with-anti-aminoacyl-trna-synthetase-antibodies
#12
Hideaki Yamakawa, Eri Hagiwara, Hideya Kitamura, Tae Iwasawa, Ryota Otoshi, Naoto Aiko, Takuma Katano, Ryota Shintani, Satoshi Ikeda, Ryo Okuda, Akimasa Sekine, Tomohisa Baba, Shinichiro Iso, Kazuyoshi Kuwano, Shinji Sato, Takashi Ogura
BACKGROUND: Little has been reported on long-term pulmonary function trends among patients with interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies (ARS-ILD). OBJECTIVES: To clarify the factors predictive of progression in ARS-ILD based on patients' initial clinical and radiological features. METHODS: The clinical courses of 88 patients with > 1 year of follow-up data on pulmonary function tests (PFTs) were retrospectively analyzed...
May 16, 2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29764848/case-of-drug-induced-interstitial-lung-disease-secondary-to-adalimumab
#13
Seema Alaee, Quentin Jones
We report a rare case of drug-induced intestinal lung disease (ILD) secondary to adalimumab, a tumour necrosis factor alpha-receptor blocker. A 52-year-old smoker with ankylosing spondylitis, treated with adalimumab, presented with progressive breathlessness. A high resolution CT chest demonstrated predominantly upper-zone patchy ground glass changes and small bilateral pleural effusions. Bronchoscopy and bronchoalveolar lavage showed no evidence of infection or malignant cells and an echocardiogram was normal...
May 15, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29764748/anticancer-drug-treatment-for-advanced-lung-cancer-with-interstitial-lung-disease
#14
REVIEW
Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi Nakanishi
Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non-small cell lung cancer (NSCLC) with ILD because of the concern of acute exacerbation, and information on the effects of immune-checkpoint inhibitors is limited in these patients...
April 13, 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29764401/management-of-acute-respiratory-failure-in-interstitial-lung-diseases-overview-and-clinical-insights
#15
REVIEW
Paola Faverio, Federica De Giacomi, Luca Sardella, Giuseppe Fiorentino, Mauro Carone, Francesco Salerno, Jousel Ora, Paola Rogliani, Giulia Pellegrino, Giuseppe Francesco Sferrazza Papa, Francesco Bini, Bruno Dino Bodini, Grazia Messinesi, Alberto Pesci, Antonio Esquinas
BACKGROUND: Interstitial lung diseases (ILDs) are a heterogeneous group of diseases characterized by widespread fibrotic and inflammatory abnormalities of the lung. Respiratory failure is a common complication in advanced stages or following acute worsening of the underlying disease. Aim of this review is to evaluate the current evidence in determining the best management of acute respiratory failure (ARF) in ILDs. METHODS: A literature search was performed in the Medline/PubMed and EMBASE databases to identify studies that investigated the management of ARF in ILDs (the last search was conducted on November 2017)...
May 15, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29763900/c-prosp-b-a-possible-biomarker-for-pulmonary-diseases
#16
Nicolas Kahn, Anne-Kathrin Rossler, Katrin Hornemann, Thomas Muley, Ekkehard Grünig, Werner Schmidt, Felix J F Herth, Michael Kreuter
BACKGROUND: Detection of surfactant proteins A and D (SP-A and SP-D) in the serum of patients with pulmonary diseases is thought to reflect an injury of the alveolar epithelial barrier and as such serve as a biomarker for these diseases. However, the data for SP-B are limited. OBJECTIVES: The aim of this feasibility study was to assess whether immature SP-B pre-proteins might have value as a possible biomarker for pulmonary diseases. METHODS: In serum samples from patients with different chronic lung diseases (interstitial lung diseases [ILDs], chronic obstructive pulmonary disease, asthma, lung cancer, pulmonary hypertension, inflammation, patients on ventilator support; total n = 283), C-proSP-B was measured using an electrochemiluminescence immunoassay based on mouse monoclonal anti-C-proSP-B antibodies...
May 15, 2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29763468/clinical-phenotypes-and-survival-of-pre-capillary-pulmonary-hypertension-in-systemic-sclerosis
#17
David Launay, David Montani, Paul M Hassoun, Vincent Cottin, Jérôme Le Pavec, Pierre Clerson, Olivier Sitbon, Xavier Jaïs, Laurent Savale, Jason Weatherald, Vincent Sobanski, Stephen C Mathai, Majid Shafiq, Jean-François Cordier, Eric Hachulla, Gérald Simonneau, Marc Humbert
Pre-capillary pulmonary hypertension (PH) in systemic sclerosis (SSc) is a heterogeneous condition with an overall bad prognosis. The objective of this study was to identify and characterize homogeneous phenotypes by a cluster analysis in SSc patients with PH. Patients were identified from two prospective cohorts from the US and France. Clinical, pulmonary function, high-resolution chest tomography, hemodynamic and survival data were extracted. We performed cluster analysis using the k-means method and compared survival between clusters using Cox regression analysis...
2018: PloS One
https://www.readbyqxmd.com/read/29757823/reliability-validity-and-responsiveness-of-the-incremental-shuttle-walk-test-in-patients-with-interstitial-lung-disease
#18
Sumedha Singh, Jamal Ali Moiz, Mir Shad Ali, Deepak Talwar
PURPOSE: To determine the reliability, validity, and responsiveness of the incremental shuttle walk test (ISWT) in patients with interstitial lung disease (ILD). METHODS: This was a cross-sectional longitudinal study. Patients (n = 27, 10 males; mean age ± SD, 61 ± 9.8 y) with ILD of any etiology, who participated in an outpatient pulmonary rehabilitation (PR) program, were recruited. Reliability was determined by comparing the distance covered in meters between the ISWT-1 and the ISWT-2...
May 11, 2018: Journal of Cardiopulmonary Rehabilitation and Prevention
https://www.readbyqxmd.com/read/29755982/clinical-genetics-in-interstitial-lung-disease
#19
REVIEW
Chad A Newton, Philip L Molyneaux, Justin M Oldham
Interstitial lung disease (ILD) comprises a heterogeneous group of diffuse parenchymal lung processes with overlapping clinical, radiographic, and histopathologic features. Among the most common and deadly ILDs are idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (CHP). As the name implies, the cause of IPF remains elusive, but a variety of genetic and infectious risk factors have been identified. CHP results from chronic inhalation of an organic antigen, usually of avian or mold origin, and may occur in patients with a genetic predisposition...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29750141/a-stepwise-composite-echocardiographic-score-predicts-severe-pulmonary-hypertension-in-patients-with-interstitial-lung-disease
#20
Simon Bax, Charlene Bredy, Aleksander Kempny, Konstantinos Dimopoulos, Anand Devaraj, Simon Walsh, Joseph Jacob, Arjun Nair, Maria Kokosi, Gregory Keir, Vasileios Kouranos, Peter M George, Colm McCabe, Michael Wilde, Athol Wells, Wei Li, Stephen John Wort, Laura C Price
European Respiratory Society (ERS) guidelines recommend the assessment of patients with interstitial lung disease (ILD) and severe pulmonary hypertension (PH), as defined by a mean pulmonary artery pressure (mPAP) ≥35 mmHg at right heart catheterisation (RHC). We developed and validated a stepwise echocardiographic score to detect severe PH using the tricuspid regurgitant velocity and right atrial pressure (right ventricular systolic pressure (RVSP)) and additional echocardiographic signs. Consecutive ILD patients with suspected PH underwent RHC between 2005 and 2015...
April 2018: ERJ Open Research
keyword
keyword
12538
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"